# Libtayo (cemiplimab-rwlc) PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/cemiplimab-rwlc

> The FDA approved Libtayo (cemiplimab-rwlc), sponsored by REGENERON PHARMACEUTICALS, INC. (REGN), on September 28, 2018.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | Libtayo (cemiplimab-rwlc) |
| Codes |  |
| Sponsor | REGENERON PHARMACEUTICALS, INC. (REGN) https://sec-api.dev/companies/regn/catalysts |
| Indications |  |
| Modality | biologic |
| FDA designations | priority review |

## Timeline

### September 28, 2018: FDA approval

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "BLA761097 ORIG-1 (Type 1 - New Molecular Entity): submission_status AP, submission_status_date 20180928, review_priority PRIORITY; sponsor_name REGENERON PHARMACEUTICALS; product LIBTAYO (CEMIPLIMAB-RWLC)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761097%22

### June 25, 2020: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "BLA761097 SUPPL-5 (Efficacy): submission_status AP, submission_status_date 20200625, review_priority STANDARD; sponsor_name REGENERON PHARMACEUTICALS; product LIBTAYO (CEMIPLIMAB-RWLC)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761097%22

### February 9, 2021: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "BLA761097 SUPPL-8 (Efficacy): submission_status AP, submission_status_date 20210209, review_priority PRIORITY; sponsor_name REGENERON PHARMACEUTICALS; product LIBTAYO (CEMIPLIMAB-RWLC)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761097%22
- openFDA Drugs@FDA: "BLA761097 SUPPL-9 (Efficacy): submission_status AP, submission_status_date 20210209, review_priority PRIORITY; sponsor_name REGENERON PHARMACEUTICALS; product LIBTAYO (CEMIPLIMAB-RWLC)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761097%22

### February 22, 2021: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "BLA761097 SUPPL-7 (Efficacy): submission_status AP, submission_status_date 20210222, review_priority PRIORITY; sponsor_name REGENERON PHARMACEUTICALS; product LIBTAYO (CEMIPLIMAB-RWLC)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761097%22

### November 8, 2022: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "BLA761097 SUPPL-14 (Efficacy): submission_status AP, submission_status_date 20221108, review_priority STANDARD; sponsor_name REGENERON PHARMACEUTICALS; product LIBTAYO (CEMIPLIMAB-RWLC)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761097%22

### April 28, 2023: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "BLA761097 SUPPL-16 (Efficacy): submission_status AP, submission_status_date 20230428, review_priority STANDARD; sponsor_name REGENERON PHARMACEUTICALS; product LIBTAYO (CEMIPLIMAB-RWLC)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761097%22
- openFDA Drugs@FDA: "BLA761097 SUPPL-15 (Efficacy): submission_status AP, submission_status_date 20230428, review_priority STANDARD; sponsor_name REGENERON PHARMACEUTICALS; product LIBTAYO (CEMIPLIMAB-RWLC)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761097%22

### April 5, 2024: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "BLA761097 SUPPL-23 (Efficacy): submission_status AP, submission_status_date 20240405, review_priority STANDARD; sponsor_name REGENERON PHARMACEUTICALS; product LIBTAYO (CEMIPLIMAB-RWLC)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761097%22

### October 8, 2025: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "BLA761097 SUPPL-30 (Efficacy): submission_status AP, submission_status_date 20251008, review_priority PRIORITY; sponsor_name REGENERON PHARMACEUTICALS; product LIBTAYO (CEMIPLIMAB-RWLC)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761097%22

### October 29, 2025: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "BLA761097 SUPPL-32 (Efficacy): submission_status AP, submission_status_date 20251029, review_priority PRIORITY; sponsor_name REGENERON PHARMACEUTICALS; product LIBTAYO (CEMIPLIMAB-RWLC)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761097%22

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/cemiplimab-rwlc.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Libtayo (cemiplimab-rwlc) PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/cemiplimab-rwlc

```bibtex
@misc{secapidev_pdufa_cemiplimab_rwlc_20261116,
  title        = {Libtayo (cemiplimab-rwlc) PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/cemiplimab-rwlc}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_cemiplimab_rwlc_20261116","title":"Libtayo (cemiplimab-rwlc) PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/cemiplimab-rwlc","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
